Form D · Biotechnology

Variant Bio, Inc.

Seattle, WA · CIK 0001790599

Offering snapshot reported Nov 17, 2021 · SEC filing

Reported sold: $105M
Investors reported: 12
Minimum accepted: $0
First sale: Oct 29, 2021

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$94,999,891 → $104,999,883
Reported investors11 → 12

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Nov 17, 2021	Amendment	$104,999,883	$9,999,992vs Nov 4, 2021	12	SEC filing
Nov 4, 2021	Initial	$94,999,891	No comparison	11	SEC filing
Aug 5, 2020	Initial	$6,099,988	No comparison	6	SEC filing
Oct 10, 2019	Initial	$16,639,530	No comparison	2	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-419841

Source: Form D, filed Nov 17, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Stephane Castel	Director, Executive
Andrew Farnum	Director, Executive
Adam Goulburn	Director
Akhila Kosaraju	Director, Executive
Bob More	Director
Stuart Nagae	Director
Julie Sunderland	Director
Elena Viboch	Director
Kaja Wasik	Director, Executive
Josh Wolfe	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

1616 Eastlake Ave E, Suite 208
Seattle, WA, 98102